N/A N=33 Young Adult Eating Habits
Eating Behavior · Eating Habit
Primary: Change in Brain Response From Baseline to 2-weeks Post High UPF or 2 Weeks no UPF Diet — 0.02; 0.13 arbitrary units
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=152 Age and Response to Flu Vaccines
Influenza · Influenza Immunisation
Primary: Magnitude of the Serum Antibody Response by Hemagglutination-inhibition (HAI) — 528 titer
Phase 1 N=130 Effects of E-Cigarette Flavors on Adults TCORS 2.0
Nicotine Use Disorder
Primary: Change Score in Liking/Wanting of E-cigarette — -1.06; -5.59; -7.14; -7.63 units on scale
Phase 1 N=12 A Single Dose Study To Test Two Pediatric Forms Of Ritlecitinib Compared With Adult Ritlecitinib In Healthy Adults
Healthy Participants
Primary: Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) for Ritlecitinib — 361.1; 370.1; 385.1 nanograms*hours/milliliter…
N/A N=199 Perceptions of Cigarette Smoking in Young Adults
Smoking, Cigarette
Primary: Subjective Response to Smoking Cigarettes From the Cigarette Evaluation Scale — 4.68; 4.50 score on a scale — p=>.05
Phase 3 N=2,284 Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years
Acellular Pertussis · Diphtheria · Tetanus
Primary: Number of Seroprotected Subjects With Anti-diphteria (Anti-D) and Anti-tetanus (Anti-T) Antibodies — 1418; 717; 1439; 728 Participants
Phase 3 N=60 A Controlled Study of Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD) in Adults
Attention Deficit Hyperactivity Disorder
Primary: Adult Attention Deficit Hyperactivity Disorder (ADHD) Investigator Symptom Rating Scale (AISRS) Total Score — -7.6; -2.1 score on a scale — p==.0106
N/A N=48 Written Language Intervention for Adults With Intellectual and Developmental Disabilities
Intellectual Disability · Developmental Disability
Primary: Use of Reading Comprehension Strategies — 3.986; 0.032 reading comprehension strategies used
Phase 2 N=129 DiaBetter Together for Young Adults With Type 1 Diabetes
Type 1 Diabetes
Primary: Glycemic Control (HbA1c) — 9.1; 6.5; 8.5; 9.2 Percentage of HbA1c
Phase 3 N=127 Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD
ADHD
Primary: Lean Squares Mean (± Standard Error) of Math Test Score Over All Post-dose Time Points (0.5, 1, 2, 4, 8, 10, 12, 13, and 14 Hours Post-dose) Assessed During the…
N/A N=3,070 Young Adult Smoker's Treatment Demand
Smoking Cessation
Primary: Program Enrollment — .05 proportion of click-throughs who enroll
N/A N=18 Noise Reduction Preferences in Teenagers and Pre-teens
Hearing Loss
Primary: Subjective Rating of Listening Effort Questionnaire — 44.73; 44.5; 41.53; 35.86 units on a scale — p=0.007
Phase 1 N=627 Safety and Immunogenicity of Three Dosage Levels of Swine Influenza Vaccine in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to <65 Years and Elderly 65 Years and Older.
Prophylaxis of A/H3N2v Influenza
Primary: Number of Subjects (3 to <9 Years of Age) Reporting Solicited Adverse Events (AEs) Following Vaccination With H3N2 Monovalent Vaccine. — 31; 36; 18; 24 Number of Subjects
N/A N=24 The Monitoring Study
Type1diabetes
Primary: Percentage of Time Spent With Dexcom CGMG < 60 mg/dl — 1.32; 1.95; 1.05; 0.99 percentage of time
N/A N=365 Cell Phone Intervention in Young Adults
Obesity
Primary: Change in Body Weight — -0.99; -2.6; -1.7 kg
Phase 2 N=341 Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004)
Streptococcus Pneumoniae Infection · Pneumococcal Infections
Primary: Percentage of Adult Participants Experiencing ≥1 Adverse Event (AE) — 100.0; 100.0 Percentage of Participants
Phase 2 N=112 ALL Adult Consortium Trial: Adult ALL Trial
Acute Lymphoblastic Leukemia
Primary: Asparaginase Completion Rate — 43; 79 Percentage of patients
Phase 2 N=601 Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above
Influenza
Primary: To Demonstrate the Equivalence of Antibody Response Against A/H5N1 Strain Elicited by the Three Different Immunization Schedules on Day 43. — 4.64; 4.10; 4.61; 14 Area…
Phase 3 N=1,533 A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above
Respiratory Syncytial Virus Infections
Primary: RSV-A Neutralization Titers Expressed as Group Geometric Mean Titer (GMT) in Healthy Participants Compared to OA-RSV Group — 7906.0; 7518.9 Titer
N/A N=100 Changing Habits and Lifestyles in Older Individuals
Eating Behaviour
Primary: Egg Intake — 5; 4 eggs
Phase 3 N=507 Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Participants
Hyperemia
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 66; 38; 44; 25 Participants
Phase 4 N=54 Unicirc Adolescent 12-15 Year Old Boys
Circumcision, Male
Primary: Intraoperative Duration — 9.5 minutes
N/A N=302 Adult Normative Performance of the Quotient ADHD System
ADHD
Primary: Well-screened, Non-ADHD Controls to Augment the Existing Adolescent and Adult Database Thus Expanding the Normative Reference Range of Performance of the Quotient®…
Phase 2 N=48 A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age
Respiratory Syncytial Viruses · Respiratory Tract Infections
Primary: Number of Participants With Solicited Local Adverse Events (AEs) for 7 Days After First Vaccination — 8; 1; 14; 4 Participants
Phase 4 N=445 Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes
Attention Deficit Hyperactivity Disorder
Primary: Mean Change in the Conners' Adult ADHD Rating Scale-Investigator Rated: Screening Version (CAARS-Inv:SV) Total ADHD Symptom Score From Baseline to 12 Week Endpoint…
N/A N=44 Expanded Indications in the Adult Cochlear Implant Population
Hearing Loss, Sensorineural
Primary: Change in Percent Correct on Word Recognition in Quiet in Implanted Ear — 25.6 Change in percentage points
N/A N=28 The Impact of Age on Adaptive Immunity in Adults Infected With Respiratory Syncytial Virus
RSV Infection
Primary: Number of Participants With Challenge-related Adverse Events — 0; 3 Participants
Phase 3 N=126 Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvanted Influenza Study Vaccine in Adults Aged 18 Years and Above
Human Influenza
Primary: Percentage of Subjects With Single Radial Hemolysis (SRH) Areas ≥25mm2, Against Each of Three Vaccine Strains After Receiving One Dose of TIVc — 66; 41; 98; 84…
N/A N=30 The Effect of Per Oral Immunotherapy in Severe Milk, Peanut and Egg Allergy in Adults
Food Allergy
Primary: Desensitisation — 7; 5; 2 Participants
Phase 4 N=1,561 A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Older
Pertussis · Tetanus · Diphtheria
Primary: Geometric Mean Titers (GMTs) of Tetanus, Diphtheria, and Pertussis Antibodies Pre- and Post-Vaccination With ADACEL® or DECAVAC® Vaccine — 0.501; 0.451; 8.43; 7.23 Titers